Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025)
Genmab A's (GMAB) quarterly Asset Writedowns and Impairment came in at $1.0 million in Q3 2025, down 90.91% on a YoY basis from $11.0 million in Q3 2024, and little changed quarter-over-quarter from $1.0 million in Q2 2025.
Powered by 
Analysis
Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Genmab A (GMAB) has reported Asset Writedowns and Impairment for 2 consecutive years, with $1.0 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 90.91% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2025 stood at $14.0 million (changed N/A YoY), and the FY2025 full-year result was $32.0 million, up 88.24% from the prior year.
- Asset Writedowns and Impairment held at $1.0 million in Q3 2025 per GMAB's latest filing, from $1.0 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $11.0 million in Q3 2024 and bottomed at $1.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Sep 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 9.00 Mn |